GSK’s (GSK) “Neutral” Rating Reiterated at UBS Group

UBS Group reiterated their neutral rating on shares of GSK (LON:GSK) in a report released on Friday, Marketbeat reports. They currently have a GBX 1,940 price target on the stock.

A number of other equities research analysts have also weighed in on GSK. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of GSK from GBX 1,600 to GBX 1,675 and gave the stock a “hold” rating in a report on Thursday, January 15th. Shore Capital reiterated a “buy” rating on shares of GSK in a research report on Thursday, January 8th. Berenberg Bank upped their target price on GSK from GBX 1,600 to GBX 1,660 and gave the company a “hold” rating in a report on Monday, November 24th. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research note on Wednesday, January 7th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,100 price target on shares of GSK in a report on Wednesday, January 7th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of GBX 1,829.17.

GSK Price Performance

Shares of LON GSK opened at GBX 1,807.64 on Friday. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. The stock’s 50-day simple moving average is GBX 1,817.89 and its two-hundred day simple moving average is GBX 1,633.24. The firm has a market capitalization of £72.92 billion, a P/E ratio of 13.59, a P/E/G ratio of 1.24 and a beta of 0.31. GSK has a twelve month low of GBX 1,242.50 and a twelve month high of GBX 1,909.73.

GSK (LON:GSK) last announced its earnings results on Wednesday, October 29th. The company reported GBX 55 earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, equities analysts anticipate that GSK will post 175.980975 EPS for the current fiscal year.

Insider Buying and Selling

In other GSK news, insider Jonathan Symonds bought 1,650 shares of the stock in a transaction dated Monday, December 22nd. The stock was purchased at an average cost of GBX 1,810 per share, for a total transaction of £29,865. Also, insider Wendy Becker purchased 441 shares of the company’s stock in a transaction dated Friday, December 19th. The stock was bought at an average cost of GBX 1,809 per share, for a total transaction of £7,977.69. 0.20% of the stock is currently owned by company insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.